BlackRock
TAK icon

BlackRock’s Takeda Pharmaceutical TAK Stock Holding History

BlackRock’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.1M Buy
3,688,166
+511,745
+16% +$8.47M ﹤0.01% 2573
2026
Q1 		$58.8M Buy
3,176,421
+444,823
+16% +$7.81M ﹤0.01% 2409
2025
Q4 		$42.6M Sell
2,731,598
-575,991
-17% -$8.24M ﹤0.01% 2628
2025
Q3 		$48.4M Sell
3,307,589
-243,288
-7% -$3.61M ﹤0.01% 2524
2025
Q2 		$54.9M Buy
3,550,877
+920,044
+35% +$13.6M ﹤0.01% 2397
2025
Q1 		$39.1M Buy
2,630,833
+426,982
+19% +$5.98M ﹤0.01% 2508
2024
Q4 		$29.2M Buy
2,203,851
+313,174
+17% +$4.3M ﹤0.01% 2806
2024
Q3 		$26.9M Buy
1,890,677
+454,325
+32% +$6.44M ﹤0.01% 2846
2024
Q2 		$18.6M Sell
1,436,352
-558,236
-28% -$7.39M ﹤0.01% 3030
2024
Q1 		$27.7M Buy
1,994,588
+222,646
+13% +$3.24M ﹤0.01% 2804
2023
Q4 		$25.3M Sell
1,771,942
-522,527
-23% -$7.41M ﹤0.01% 2876
2023
Q3 		$35.5M Sell
2,294,469
-112,430
-5% -$1.74M ﹤0.01% 2614
2023
Q2 		$37.8M Sell
2,406,899
-139,117
-5% -$2.28M ﹤0.01% 2661
2023
Q1 		$42M Buy
2,546,016
+460,180
+22% +$7.33M ﹤0.01% 2570
2022
Q4 		$32.5M Sell
2,085,836
-145,161
-7% -$2.03M ﹤0.01% 2756
2022
Q3 		$28.9M Buy
2,230,997
+53,234
+2% +$740K ﹤0.01% 2826
2022
Q2 		$30.6M Sell
2,177,763
-843,511
-28% -$12M ﹤0.01% 2833
2022
Q1 		$43.3M Buy
3,021,274
+842,139
+39% +$12.4M ﹤0.01% 2669
2021
Q4 		$29.7M Buy
2,179,135
+365,186
+20% +$5.12M ﹤0.01% 3022
2021
Q3 		$29.7M Buy
1,813,949
+138,422
+8% +$2.32M ﹤0.01% 3023
2021
Q2 		$28.2M Buy
1,675,527
+307,522
+22% +$5.23M ﹤0.01% 3086
2021
Q1 		$25M Buy
1,368,005
+1,367,308
+196,170% +$24.6M ﹤0.01% 3059
2020
Q4 		$13K Buy
697
+39
+6% +$684 ﹤0.01% 4827
2020
Q3 		$12K Buy
+658
New +$12K ﹤0.01% 4783
2020
Q1 		– Sell
-66
Closed -$1K – 5076
2019
Q4 		$1K Sell
66
-237
-78% -$4.53K ﹤0.01% 4952
2019
Q3 		$5K Sell
303
-2,158
-88% -$37.3K ﹤0.01% 4786
2019
Q2 		$43K Buy
2,461
+1,563
+174% +$28.4K ﹤0.01% 4598
2019
Q1 		$18K Buy
898
+718
+399% +$14.4K ﹤0.01% 4615
2018
Q4 		$3K Buy
+180
New +$3.04K ﹤0.01% 4802

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

BlackRock's TAK Position: Q2 2026 in Review

BlackRock increased its Takeda Pharmaceutical (TAK) stake by 16% in Q2 2026, buying an estimated $8.47M and bringing the position to 3,688,166 shares worth $59.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2573.

BlackRock first reported a position in TAK in Q4 2018 and has held it in 29 quarters since. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • BlackRock held 3,688,166 shares of Takeda Pharmaceutical worth $59.1M as of Q2 2026.
  • BlackRock bought 511,745 Takeda Pharmaceutical shares in Q2 2026, an estimated $8.47M.
  • Takeda Pharmaceutical made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2573 holding.
  • BlackRock first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 29 quarters since.
  • 375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.